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MYOCARDIAL INFARCTION 
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Objectives. This study was performed to evaluate the effects of 
t.carnitine administration on long-term left ventricular dilation 
in patients with acute anterior myocardial infarction. 
Background. Carnitine is a physiologic compound that per- 
forms an essential role in myocardial energy production at the 
mitochondrial level. Myocardial carnitine deprivation occurs dur- 
ing ischemia, acute myocardial infarction and cardiac failure. 
Experimental studies have suggested that exogenous carnitine 
administration during these events has a beneficial effect on 
function. 
Methods. The L-Carnitine Ecocardiografia Digitalizzata Infarto 
Miocardico (CEDIM) trial was a randomized, double-blind, 
placebo-controlled, muiticenter trial in which 472 patients with a 
first acute myocardial infarction and high quality two- 
dimensional echocardiogcams received either placebo (239 pa- 
tients) or L-carnitine (233 patients) within 24 h of onset of chest 
pain. Placebo or L-carnitine was given at a dose of 9 g/day 
intravenously foz the first 5 days and then 6 g/day orally for the 
next 12 months. Left ventricular volumes and ejection fraction 
were evaluated on admission, at discharge from hospital and at 3, 
6 and 12 months after acute myocardial infarction. 
Results. A significant attenuation of left ventricular dilation in 
the first year after acute myocardial infarction was observed in 
patients treated with L-carnitine compared with those receiving 
placebo. The percent increase in both end-diastolic and end- 
systolic volumes from admission to 3-, 6- and 12-month evaluation 
was significantly reduced in the t-carnitine group. No significant 
differences were observed in left ventricular ejection fraction 
changes over time in the two groups. Although not designed to 
demonstrate differences in clinical end points, the combined 
incidence of death and congestive heart failure after discharge was 
14 (6%) in the L-carnitine treatment group versus 23 (9.6%) in the 
placebo group (p = NS). Incidence of ischemic events during 
follow-up was similar in the two groups of patients. 
Conclusions. t-Carnitine treatment initiated early after acute 
myocardial infarction and continued for 12 months can attenuate 
left ventricular dilation during the first year after an acute 
myocardial infarction, resulting in smaller left ventricnlar vol- 
umes at 3, 6 and 12 months after the emergent event. 
(J Am Coil Cardiol 1995;26:380-7) 
Acute myocardial infarction often results in regional left 
ventricular dysfunction and, as a consequence, produces pro- 
gressive left ventricular dilation (left ventricular remodeling) 
(I). Left ventricular dilation after acute myocardial infarction 
develops initially not only because of possible xpansion of the 
infarcted zone (2), but also because of adaptive l ngthening of 
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noninfarcted myocardium (3). Left ventricular dilation after 
acute myocardial infarction can be considered a response to 
regional dysfunction, aimed at maintaining an adequate stroke 
volume despite the decline in ejection fraction. 
The entity of left ventricular dilation after acute myocardial 
infarction, in particular end-systolic volume, represents the 
most powerful prognostic indicator for clinical events. Patients 
with larger ventricles are at higher risk of cardiac failure and 
death (4). It has also been demonstrated that limitation of the 
left ventricular dilation process after acute myocardial infarc- 
tion can exert a significant clinical benefit (5). Therefore, much 
effort has been devoted to developing and evaluating thera- 
peutic strategies capable of limiting left ventricular dilation 
after acute myocardial infarction. These show that left ventrie- 
ular dilation can be modulated by 1) limiting the infarct size 
itself (the most important determinant of subsequent left 
ventricular dilation) with timely reperfusion of the infarct 
0735-1097/95/$9.50 
0735-1097(95)00182-4 
JACC Vol. 26, No. 2 ILICETO ET AL. 381 
August 1995:380-7 CARNITINE IN ACUTE MYOCARDIAL INFARCTION 
region (6); and 2) reducing left ventricular wall stress, and 
hence progressive l ft ventricular dilation of the noninfarcted 
region with angiotensin-converting enzyme inhibitor therapy 
(7-9). 
Carnitine is a physiologic ompound (a quaternary amine) 
that plays an essential role in the production of myocardial 
energy at the mitochondriai level. It reduces the ischemia 
induced increase in long-chain fatty acid concentration and 
thus mitigates its deleterious functional effects (10,11). Exper- 
imental and clinical studies have shown that in the ischemic 
(12,13), infarcted (14,15) or failing myocardium (16,17), car- 
nitine depletion occurs rapidly. Conversely, exogenous admin- 
istration can restore adequate intramyocardial camitine levels 
with a suggested consequent beneficial effect on myocardial 
function (18-22). Because of these properties we hypothesized 
that early administration of carnitine after acute myocardial 
infarction could limit the deleterious phenomenon ofprogres- 
sive left ventricular dilation. 
To test this hypothesis, we undertook a multicenter, an- 
domized, double-blind, placebo-controlled study: the Car- 
nitina, Ecocardiografia Digitalizzata, Infarto Miocardico 
(CEDIM) trial. 
Methods 
The CEDIM trial involved the intensive cardiac are units 
at 36 divisions of cardiology in Italy. Patients ---80 years old 
with acute myocardial infarction were entered into the study if: 
1) the infarct was anterior; 2) admission to the intensive care 
unit occurred within 24 h of onset of chest pain; 3) echocar- 
diographic imaging of the left ventricle was of excellent quality, 
allowing delineation of the left ventricular contours in both 
end-diastole and end-systole of at least 85% of the left 
ventricular endocardial border; and 4) study treatment (place- 
bo or L-carnitine) could be initiated within 24 h from onset of 
chest pain. A diagnosis of anterior acute myocardial infarction 
was made if typical chest pain lasted >30 min, with ST 
elevation in at least two anterior leads of >-2 mm and not 
relieved by nitroglycerin. Exclusion criteria included the fol- 
lowing: 1) a previous myocardial infarction, valvular or con- 
genital heart disease or cardiomyopathy; 2) absence of sinus 
rhythm; 3) left bundle branch block; 4) conditions or concom- 
itant diseases that could affect follow-up; 5) inclusion in 
another investigation. 
Study design. Placebo and L-camitine were administered 
in the following manner: 9 g/day, by continuous intravenous 
infusion, for the first 5 days, and then 6 g/day orally (2 g, three 
times/day) for the next 12 months. L-Carnitine or placebo was 
added to the standard therapeutic strategies adopted at each 
institution. Drugs with a direct effect on cardiac metabolism 
were not permitted. Because, at the time of the study onset in 
November 1991, the Survival and Ventricular Enlargement 
(SAVE) trial (7) results were not known, angiotensin- 
converting enzyme inhibitor therapy was not recommended 
and hence not systematically provided. As a result angiotensin- 
converting enzyme inhibitor therapy was given to only 8% of 
patients. However, on the basis of its proven efficacy, throm- 
bolytic therapy was provided for 78% of patients. The study 
was approved by an independent ethical committee, and 
informed consent (either written or oral in the presence of a 
witness) was obtained from all patients included. 
Methods ofassessment. The primary end points of the trial 
were left ventricular volumes and ejection fraction at 12 
months after the emergent event assessed by two-dimensional 
echocardiography. This assessment was performed at baseline 
(before randomization, at 11.6 +_ 6.9 h from onset of chest 
pain) and again at discharge, as well as at 3, 6 and 12 months 
after acute myocardial infarction. Results are expressed as 
percent change for each variable. Although all available tomo- 
graphic planes were obtained, only apical four- and two- 
chamber views were considered for volume assessment. All 
echocardiographic examinations were digitally recorded and 
sent for analysis to a central core laboratory. Real-time 
transfer to the core laboratory was achieved by means of a 
digital network whose characteristics have previously been 
described in detail (23). Briefly, equipment capable of convert- 
ing video images into digital ones (PreVue III, Nova Microson- 
ics) was installed in each of the 36 centers. The images were 
then loaded on a review station (modified 386 PC) connected 
to a high speed modem (Digicom SNM 32) and to a dedicated 
telephone line. At the core laboratory the images were re- 
ceived by modem and then studied on an ImageView review 
station (Nova) for quantitative assessment. All left ventricular 
volume measurements were obtained by averaging four con- 
secutive cardiac ycles by the same observer (G.S.). The same 
network was used for central (24-h/day) verification of eligibil- 
ity criteria and randomization of enrolled patients. 
Statistical analysis. Primary analysis. The primary aim of 
the present study was to compare left ventricular ejection 
fraction and end-diastolic and end-systolic volumes in the two 
treatment arms at 12 months after randomization. Patients 
who, because of death or refusal, did not have the echocardio- 
graphic examination at 12 months, were excluded from the 
analyses. The differences were adjusted for baseline values by 
analysis of covariance. It has been demonstrated repeatedly 
(24) that the adjusted ifference represents he appropriate 
tool for reducing variability in the outcome variable by taking 
into account baseline values. Baseline values were not avail- 
able for 35 patients because of inadequacy of baseline cho- 
cardiographic recording or problems in digital format acquisi- 
tion, or both. Baseline values were estimated using the AM 
procedure of BMDP statistical software (25,26). Analyses 
including and excluding these patients with estimated baseline 
values provided virtually identical results, and only the latter 
are presented. Analyses of patients with baseline and final 
values were performed according to intention to treat. 
Secondary analyses. The differences, adjusted for baseline 
values, between the two study arms, at discharge and after 3 
and 6 months, were also analyzed using analysis of covariance. 
As a consequence of the increasing number of deaths and 
withdrawals over time, different numbers of patients were 
included in the various analyses. Comparison of percent 
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change in left ventricular volume measurements between the 
two treatment groups were made by means of the Student t test 
for unpaired ata. All p values are two-tailed. Significance was 
established at p < 0.05. 
Sample size. The study was designed to detect a 5% 
absolute difference in left ventricular ejection fraction at 12 
months between the two study arms, with an 80% power for a 
significance l vel of 0.05. On the basis of published reports, it 
was assumed that left ventricular ejection fractioa had a 
standard eviation of 15%; therefore, atleast 280 patients had 
to be recruited. However, to allow for deaths and withdrawals, 
and for lack of normality of outcome variables, it was decided 
to enroll at least 400 patients in the study. 
Reproducibility. To evaluate the reproducibility of the 
two-dimensional echocardiographic evaluation of end-diastolic 
and end-systolic volumes, 30 randomly selected echocardio- 
grams were evaluated three times by the same cardiologist who 
performed all the cchocardiographic measurements in the 
CEDIM study. These echocardiograms were reexamined at
random and without knowledge of the patient's identity or 
previous evaluation results. Variance of the three repeated 
measures was calculated for each subject. Intraobserver vari- 
ance was estimated as the average of the values obtained for 
the 30 subjects. Reproducibility, expressed as standard efla- 
tion (square root of intraobserver variance), was 2.366 ml for 
end-diastolic volume and 2.047 ml for end-systolic volume 
(mean value 88.29 ml for end-diastolic volume, 45.28 ml for 
end-systolic volume). 
All analyses were performed using BMDP statistical soft- 
ware for Windows and SPSS for Windows (25,27). 
Results 
Four hundred seventy-two patients were enrolled in the 
CEDIM trial: 239 patients received placebo and 233 L- 
carnitine; treatment was administered 12.7 + 7.17 h after onset 
of chest pain. Of the 472 pat~.ents enrolled in the study, 348 
were considered for analysis because they had paired echocar- 
diograms (baseline to 12 months) available. Reasons for 
withdrawal of the 124 patients were as follows: 48 patients 
(10.1%) died; 45 (9.5%) were either lost to follow-up or 
refused to return for periodic control evaluation; 35 (7.4%) 
had an inadequate baseline echocardiogram (problems in 
digital procedure or poor echocardiographic quality). Baseline 
clinical and echocardiographic characteristics ofthe two treat- 
ment groups were similar and are presented in Table 1. 
Echocardiographie examinations were performed 11.6 +__ 
6.93 h after onset of chest pain. Patients considered for final 
analysis (n = 348) were comparable to the overall group of 
patients (n = 472) participating in the trial. Drug therapies 
prescribed at hospital discharge are given in Table 2. 
Echocardiographic results. The adjusted differences for 
end-diastolic and end-systolic volumes and ejection fraction 
between the placebo and t.-camitine groups at discharge and at 
3, 6 and 12 months after acute myocardial infarction are 
presented in Table 3. In L-carnitine-treated patients both 
end-diastolic and end-systolic volumes were significantly 
smaller at 3, 6 and 12 months after acute myocardial infarction; 
nonsignificant, lower end-diastolic and end-systolic volumes 
were also observed as early as at hospital discharge. Left 
ventricular ejection fraction was not significantly different in 
the two groups at 1 year after acute myocardial infarction. 
In patients treated with L-carnitine, progressive l ft ventric- 
ular dilation, as shown by the percent increase in both end- 
diastolic and end-systolic volumes from baseline to discharge 
and to 3, 6 and 12 months after acute myocardial infarction, 
was less pronounced than that in patients treated with placebo 
(Table 3, Fig. 1). Left ventricular ejection fraction changes 
were similar in the two treatment groups during the follow-up 
period (Table 4). 
Clinical results. Clinical events during the hospital and 
follow-up periods in the two treatment groups are shown in 
Table 5. A lower (but obviously not significantly different, 
because of nonappropriate study population dimension) num- 
ber of deaths and fewer patients with cardiac failure after 
discharge were observed in the L-carnitine group than in the 
placebo group. The number of patients with isehemic events at 
follow-up was similar in the two groups of patients. 
In none of the patients included in the trial did treatment 
have to be interrupted because of adverse vents. 
Discussion 
Prevention of left ventricular remodeling is a major thera- 
peutic goal after acute myocardial infarction. Several random- 
ized, placebo-controlled trials (28-34) have dearly shown that 
angiotensin-converting e zyme inhibitor therapy is effective in 
limiting or even preventing the phenomenon f left ventricular 
remodeling after myocardial infarction. Differences in the 
degree of efficacy among various tudies can be explained by 
different study characteristics, such as time of start of treat- 
ment after the emergent event (within hours, days or even 
weeks after admission to hospital), angiotensin-converting 
enzyme inhibitor agent or its dosage and concomitant thera- 
pies. In addition, in these studies the characteristics of enrolled 
patients (all patients with myocardial infarction, only anterior 
myocardial infarction or only those with left ventricular dys- 
function as assessed by left ventricular ejection fraction) as well 
as the duration of treatment and consequent schedule of left 
ventricular evaluations in the follow-up period, influenced the 
reported outcome. However, even if beneficial in patients with 
recent myocardial infarction, angiotensin-converting enzyme 
inhibitor therapy has to be discontinued in some patients 
because of adverse vents, such as symptomatic hypotension, 
cough, diarrhea nd dizziness, all of which limit its clinical 
applicability. 
Results of the CEDIM trial demonstrate hat early and 
long-term administration f carnitine in patients with acute 
myocardial infarction is effective in attenuating progressive l ft 
ventricular dilation. Patients treated with L-carnitine had a 
significantly lower pronounced percent increase in both end- 
diastolic and end-systolic volumes than with the control group 
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Table 1. Baseline Characteristics byTreatment for All Randomized Patients (n = 472) and Those 
With Paired Echocardiographic Examinations (n = 348) 
All Patients Patients With Paired Echo Data 
t-Carnitine Placebo t-Carnitine Placebo 
(n = 233) (n = 239) (n = 176) (n = 172) 
Age (yr) 60 ± I1 58 ± 12 58 +- 11 56 ± 12 
Gender (M/F) 195/38 204/35 150/26 151/21 
History 
Hypereholesterolemia 59 (25%) 70 (29%) 50 (28%) 49 (28%) 
Hypertension 97 (42%) 88 (37%) 71 (40%) 57 (33%) 
Current smoker 108 (46%) 124 (52%) 84 (48%) 98 (57%) 
Previous CABG or PTCA 1 (0.4%) 3 (1.2%) --  3 (1.7%) 
HR (beats/min) 81 ± 19 81 ± 16 80 ± 17 ,~0 ± 15 
SBP (ram Hg) 139 ± 25 136 ± 23 139 ± 24 136 ± 23 
DBP (ram Hg) 87 ± 14 89 ± 13 ~7 ± 14 54 ± 14 
Killip class at admission 
I 177 (76%) 182 (76%) 145 (82%) 140 (81%) 
It 51 (22%) 54 (23%) 29 (17%) 32 (19%) 
Ul 5 (2%) 2 (0.8%) 2 (1%) --  
IV --  l (0.2%) - -  - -  
Peak CK (U/liter) 1,948 ± 1,962 1,972 +_ 1,816 1,944 ± 1,581 2,120 -- 1,883 
Peak CK-MB (U/liter) 246 ± 310 229 ± 225 2,t4 ± 312 265 ~ 234 
Thrombolysis 185 (79%) 185 (77%) 141 (80%) 138 (80%) 
<-3 h 119 (51%) 125 (52%) 89 (51%) 98 (57%) 
>3 h 66 (28%) 60 (25%) 52 (29%) 40 (23%) 
Q wave 160 (69%) 164 (69%) 127 (72%) 123 (71%) 
Time to echo (rain) 737 +_ 424 651 --- 405 75fi _ 431 660 ± 415 
EDV at admission (ml) 87 ± 24 85 ± 23 87 ± 24 85 _+ 23 
ESV at admission (ml) 46 ± 15 45 +_. 16 45 *-. 16 44 _ 16 
EF (%) 48 ± 7 48 +-. 7 49 • 6 49 ± 7 
Data are expressed as mean value - SD or number (%) of patients. CABG = coronary artery bypass grafting; CK = 
creatine kinase; DBP = diastolic blood pressure; Echo, echo = eehoeardiographic, eehocardiography; EDV = 
end-diastolic volume; EF = ejection fraction; ESV = end-systolic volume; F = female; HR = heart rate; M = male; 
PTCA = pcrcutaneous transluminal coronary angioplasty; SBP = systolic blood pressure. 
at 3 months (end-diastolic volume 18.0 +-- 2.5% vs. 11.1 +_ 
2.2%; end-systolic volume 22.5 --_ 3.2% vs. 12.6 +- 3.1% 
[placebo vs. L-earnitine]), 6 months (end-diastolic volume 
19.5 _ 2.3% vs. 12.7 +__ 2.1%; end-systolic volume 25.5 - 3,2% 
vs. 15.1 +__ 9.8% [placebo and L-carnitine]) and 12 months 
(end-diastolic volume 28.5 +-- 3. l% vs. 19.1 +_ 2.7%; end- 
systolic volume 39.9 +- 4.2% vs. 28.9 +_ 3.9% [placebo vs. 
L-carnitine]) after the emergent event. Also, whereas only 8% 
Table 2. Concomitant Therapies at Hospital Discharge 
L-Camitine Placebo 
[no. (%) of pts] [no. (%) of pts] 
Digitalis 24 (10.3) 23 (9.6) 
Diuretic drugs 40 (17.2) 44 (18.4) 
Antiplatelet agents 163 (70) 167 (69.9) 
Anticoagulant agents 65 (27.9) 63 (26,4) 
ACE inhibitors 16 (6.9) 20 (8.4) 
Beta-blockers 75 (32.2) 91 {38.1) 
Nitrates 137 (58.8) 142 (59.4) 
Calcium antagonists 59 (25.3) 56 (23.4) 
Autiarrhythmie drugs 19 (8.2) I 1 (4.6) 
ACE = angiotensin-converting enzyme; pts = patients. 
of the study patients received angiotensin-converting enzyme 
inhibitors, the magnitude of the carnitine effect on the echo- 
cardiographic variables was of a similar degree to chat initially 
reported by Sharpe et ai. (30) and to that observed in some 
ancillary echocardiographic studies of large trials (Second 
Cooperative North Scandanavian Enalapril Survival Study 
[CONSENSUS II] and SAVE) (5,34,35). 
The observed effect of L-carnitine in limiting progressive 
left ventricular dilation after myocardial infarction can be 
explained by its metabolic properties and consequent func- 
tional effect. Carnitine is an essential factor in the production 
of energy within the myocardium: It facilitates the transport 
and metabolism of long-chain fatty acids, the preferred sub- 
strate for the production of metabolic energy in the heart, from 
the cytosol to the mitochondriai matrix where beta-oxidation 
occurs; moreover, it also removes compounds that are toxic to 
metabolic pathways. Carnitine deficiency within the myocar- 
dium can be primary or secondary to various conditions, 
including acute ischemia (12-15) and chronic cardiac failure 
(16). Experimental and clinical studies have shown that in 
situations characterized by its deprivation, exogenous admin- 
istration of carnitine exerts a beneficial functional effect as 
384 ILICETO ET AL. .IACC Vol. 26, No. 2 
CARNITINE IN ACUTE MYOCARDIAL INFARCTION August 1995:380-7 
Table 3. Comparison of Two-Dimensional Echoeardiographic Data at Hospital Discharge and During 
12 Months of Follow-Up Adjusted for Baseline (recovery) Values by Means of Analysis of Covariance 
L-Carnitine Placebo Adjusted 
(mean ± SE) (mean ± SE) Difference SE p Value 
Discharge n = 202 n = 206 
EDV (ml) 90.9 ± 2.33 91.7 ± 2.03 -2.54* 1.790 0.15 
ESV (ml) 47.8 ± 1.16 48.8 + 1.53 -2.02* 1.334 0.13 
EF (%) 48.1 ± 0.47 48.1 ± 0.52 +0.11 0.548 0.83 
3 mo n = 185 n = 179 
EDV (ml) 92.3 ± 1.67 97.2 ± 2.03 .-5.35 2.299 0.02 
ESV (ml) 47.8 ± 1.18 52.3 ± 1.56 -4.85 1.716 0.007 
EF (%) 48.9 ± 0.49 47.4 ± 0.56 +1.42 0.676 0.03 
6 mo n = 175 n = 176 
EDV (ml) 95.5 ± 1.97 99.1 ± 2.14 -5.01 2.316 0.03 
ESV (ml) 49.8 ± 0.51 53.3 ± 1.53 -4.29 1.613 0.008 
EF (%) 48.4 ± 0.50 47.3 ± 0.55 +1.19 0.692 0.08 
12 mo n = 176 n = 172 
EDV (ml) 99.3 ± 2.06 105.4 ± 2.37 -7.23 2.849 0.01 
ESV (ml) 55.0 ± 1.63 58.9 ± 1.75 -4A9 2.179 0.03 
EF (%) 45.8 ± 0.57 45.2 ± 0.52 +0.52 0.720 0.46 
*A significant egative interaction (p< 0.05) was present between treatment and final values. Abbreviations a in 
Table 1. 
expressed by improved cardiac performance (18,19) and toler- 
ance to myocardial ischemia (20-22). 
The results of the CEDIM trial parallel some recent 
experimental cbservations (36) in a rat model of acute myo- 
cardial infarction. Administration of a derivative of carnitine 
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Figure 1. Percent change in end-diastolic volume 
(EDV) (top) and end-systolic volume (ESV) (bot- 
tom) from baseline (hospital admission) to hospital 
discharge (3, 6 and 12 months) in the two treatment 
groups (mean value +_ 95% confidence interval). 
JACC Vol. 26, No. 2 ILICE'IO ET AL. 385 
August 1995:380-7 CARNITINE IN ACUTE MYOCARDIAL INFARCTION 
Table 4. Percent Change in End-Diastolic and End-Systolic 
Volumes and Ejection Fraction From Hospital Admission to 
Discharge and at 3, 6 and 12 Months in the Two Treatment Groups 
L-Carnitine Placebo p 
(mean ± SE) (mean ± SE) Value 
Discharse n = 202 n = 206 
EDV (ml) 6.9 ± 1.4 9.6 ± 1.7 0.21 
ESV (ml) 7.7 ± 1.7 11.0 ± 0.8 0.21 
EF (%) 0.6 ± 0.9 0.4 -- 1.0 0.86 
3 mo ,a = 185 n = 179 
EDV (ml) ILl ± 2.2 18.0 ± 2.5 0.04 
ESV (ml) 12.6 --. 3.1 22.5 ± 3.2 0.02 
EF (%) 2.1 ± 1.2 -0.7 ± 1 ? 0.09 
6 ,,no n = 175 n = 176 
EDV (ml) 12.7 -+ 2.1 19.5 ± 2.3 0.02 
ESV (ml) 15.1 ± 2.8 22.5 ± 3.2 0.01 
EF (%) 1.01 ± 1.2 -1.9 ± 1.2 0.09 
12 mo n = 176 n = 172 
EDV (ml) 19.1 ± 2.7 28.5 ± 3.1 0.02 
ESV (ml) 29.0 ± 3.9 39.9 ± 4.2 0.05 
EF (%) -5.0 ± 1.2 -5.6 ± 1.2 0.70 
Abbreviations as in Table 1. 
tion was induced by coronary ligation, significantly decreased 
the magnitude of left ventricular dilation after myocardial 
infarction (117% in the control group vs. 36% in the group of 
animals treated with propionyl-carnitine). This beneficial effect 
on left ventricular function was similar to that observed in a 
third group of rats treated with enalapril (43%). It was 
suggested that such a beneficial effect on progressive left 
ventricular dilation after myocardial infarction could be due to 
a direct action of propionyl-carnitine onviable but jeopardized 
myocytes outside the infarct zone because it did not appear to 
alter left ventricular loading. The beneficial effect of earnitine 
on left ventricular emodeling after myocardial infarction ca~ 
also be explained by its influence on regional eft ventricular 
function in dysfunctioning but live myocardium surrounding 
the necrotic zone. In fact, it has been demonstrated (37) in an 
experimental model of myocardial ischemia-reperfusion that 
carnitine significantly reverses mechanical dysfunction both 
during myocardial ischemia and reperfusion. This beneficial 
carnitine ffect on viable myocardium after myocardial infarc- 
tion may have important clinical implications, because in 
myocardial infarction patients with viable myocardium left 
ventricular dilation is less pronounced than in those in whom 
no viable tissue could be demonstrated (38). 
CEDIM trial: methodolegie considerations. A significant 
shortcoming of the CEDIM trial is the absence of serum or 
urine levels of carnitine, with tissue levels for obvious reasons 
being impossible to obtain. Nevertheless, from other studies of 
experimental nd clinical nature (12-17) rapid depletion of 
tissue and serum levels of carnitiae, with increased excretion in 
the urine, have been demonstrated in different clinical con- 
texts. Such deprivation can occur ql,ite rapidly as shown by 
Shug et al. (12). Also, Bartels et al. (39) was able to show 
excess release of carnitine in the coronary sinus when heart 
Table S. Clinical Events During Hospital and Follow-Up Periods 
L-Camitine Placebo 
[no. (%) of pts] [no. (%) of pts] 
In-hospital 
Death 11 (4.7) 14 (5.9) 
Heart failure 42 (18) 38 (15.1) 
Pulmonary ,edema 11 (4.7) 11 (4.6) 
Shock 5 (2.1) 7 (2.9) 
Early postinf;~rction a gina 26 (11.1) 23 (9.6) 
Reinfarction 6 (2.6) 5 (2.1) 
Any of these 72 (30.9) 70 (29.3) 
One-year follow-up 
Death 10 (4.3) 13 (5.4) 
Heart failure 4 (1.7) 10 (4.2) 
Unstable angina 21 (9) 21 (8.8) 
Reinfarction 5 (2.1) 5 (2.1) 
Bypass urgery 33 (14.2) 31 (13) 
PTCA 23 (9.9) 24 (10) 
Any of these 70 (30) 71 (29.7) 
Abbreviations as in I" ables 1 and 2. 
rates were increased r,apidly to ischemic onditions as shown by 
excessive lactate relea:~e. 
Similar to other triads with analogous left ventricalar func- 
tional end points, we considered, for final am.lysis, only 
patients in whom paired echocardiographic evaluations (base- 
line to follow-up) wc-e awailable. As a consequence, patients 
who died or were lost to follow-up were excluded from the 
assessment of the final restdts. The possibility that the observed 
difference is due to bias ca,.ised by patients not included in the 
analyses can be ruled out by comparing the proportion of 
withdrawals and the reasons for withdrawal in the two groups. 
In contrast to the majority of .studies aimed at the evaluation of 
therapeutic interventions aft, er acute myocardial infarction, 
baseline echocardiographic ewaluations in the CEDIM trial 
were collected very early (11£~ - 6.9 h [mean +- SD]) after 
onset oi chest pain and immediately before treatment and 
repeated upon discharge. 
In the CEDIM trial, to optitanize left ventricular volume 
evaluation accuracy and to miniir, dze observer variability, only 
patients with high quality echoc ardiograms were admitted. 
Furthermore, echocardiograms w,~.re digitized and centrally 
evaluated in a core laboratory wl lere a single observer e- 
viewed and evaluated all studies. Also, all left ventricular 
volume valuations were the results t ff the averaging of volume 
values obtained from four digitized cardiac cycles. 
In the CEDIM trial only patie~ts with anterior acute 
myocardial infarction were studied; therefore, the CEDIM 
results cannot be extrapolated to pat ients with other acute 
myocardial infarction locations. 
Because in the CEDIM trial L-carnith ae was administered at
12.7 _ 7.2 h from onset of sudden chest 13'ain it is possible that 
still earlier administration might have ex'erted a barther pro- 
tective effect on isehemia-reflow dysfunction within the risk 
area (37). Whereas this delay in administ,,ation of treatment 
was contingent on the requirement for two. dimensional echo- 
386 ILICETO ET AL. JACC Vol. 26. No. 2 
CARNITINE IN ACUTE MYOCARDIAL INFARCTION August 1995:380-7 
cardiographic quality as an inclusion criteria, a subsequent 
study in which camitine is immediately administered together 
with reperfusion therapy would be useful in evalttating its 
potential in limiting ischemic-reperfusion damage." and its 
consequent effect on left ventricular dilation. Such a project 
including larger numbers of patients, aimed at estabhshing mor- 
bidity and mortality end points rather than functional parameters, 
as this study set out to achieve, iscurrently in preparation. 
Although the present study was not designed, to show any 
significant difference in clinical end points, the combined 
occurrence of death and heart failure after di:;charge was 14 
patients in the L-carnitine-treated group verso.s 24 patients in 
the placebo group. These differences, althoug'a not significant, 
are consistent with a beneficial effect of the compound on the 
clinical events as well. It is to be noted tb,at there were no 
differences in the occurrence of other clinical end points 
including myocardial ischemia which would reflect no action of 
the drug on the coronary artery system it self but only on the 
myocytes. 
The functional benefit of L-carnitine treatment of patients 
with acute myocardial infarction can rel:,resent the conceptual 
basis for a larger scale trial specifically ,designed and aimed at 
evaluating the clinical impact of met~,bolic therapy of acute 
myocardial infarction. 
Conclusions. Carnitine administra.tion after anterior acute 
myocardial infarction exerts a benefl, cial effect on left ventric- 
ular remodeling, with a significant reduction in the increase in 
left ventricular volumes in the first ~ear after acute myocardial 
infarction. This functional effect is observed as early as 3 
months after acute myocardial ir lfarction. It has potentially 
important clinical implications b,ecause, as recently demon- 
strated by others (5), the increa:ie in left ventricular area (an 
indirect estimate of left ventrict Jlar volumes) in the first year 
after acute myocardial infarcti on is a po~verful predictor of 
future major cardiac events. Tlle potentiai dinical benefit of 
the administration fthis natu.rally occurring substance (40) in 
patients after acute myocardial infarction eeds to be verified 
in a larger trial with clinical end points. 
The mechanism of action of carnitine on left ventricular 
function and remodeling is!)resumed to be the optimization of 
disturbed cellular oxidativ e metabolism with restoration of 
adequate myocardial carni.tine levels. 
We thank Kate Hunt for cor ttinued assistance in the preparation f the 
manuscript and Patrizia Costan tino for secretarial assistance. 
Appendix 
Participating lnstit utions and Investigators for the 
CEDIM Trial* 
Chairman: Paolo Riz; :on, Bari. 
Steering Committee: Paolo Rizzon, Sabino Iliceto, Bari; Domenico Scruti- 
nio, Cassano; Paolo Brm ,.zi, Genoa; Paul G. Hugenholtz, Geneva. 
*All cities are in I' :aly. 
Scientific Committee: Antonino Brusea, Torino; Salvatore Caponnetto, 
Genova; Angelo Cherchi, Cagliari; Massimo Chiariello, Napoli; Armando Dagi- 
anti, Filippo Milazzotto, Roma; Sergio DaUa Volta, Padova; Giorgio Feruglio, 
Udine; Maurizio Guazzi, Antonio Lotto, Milano; Bruno Magnani, Bologna; 
Giorgio Mattioli, Moclena; Mario Mariani, lisa; Eligio Piccolo, Mestre; Paolo 
Rizzon, Bari; Paolo Rossi, Novara; Odoardo Visioli, Brescia. 
Data Center Committee: Sabino Iliceto, Vito Marangelli, Giuseppe Santoro, 
Gaetano D'Ambrosio, Bari. 
Ethical Committee: Antonio Iandolo, Giuseppe Brindicci, Nicola Simonetti, 
Emanuele Scardicchio, Francesca Avolio, Bari. 
Participating Centers: Francesco Girardi, Giuliano Ciociola, Acquaviva; 
Luigi Colonna, Carlo D'Agostino, Francesco Bovenzi, Paolo Rizzon, Vito 
Marangelli, Bari; Bruno Magnani, Marinella Ferlito, Paolo Ortolanai, Bologna; 
Odoardo Visioli, Mario Gargano, Giovanni La Canna, Brescia; Angelo Chercni, 
Luigi Meloni, Federico Balatta, Cagliari; Salvatore Mangiameli, Giaeomo Chi- 
arand~t, Angela Lazzaro, Catania; Aleardo Maresta, Flaviano Jacopi, Faenza; 
Aldo leri, Marco Sansoni, Fucecchio; Salvatore Caponnetto, Giovanni Gnecco, 
Genova; Pasquale Marsili~ Claudio Corridoni, L'Aquila; Francesco Bacca, 
Francesco Spirito, Lecce; Mario Sanguinetti, Roberto Mantovani, Lugo; Luciano 
Tantalo, Giancarlo Calculli, Matera; Eligio Piccolo, Bruno De Piccoli, Fausto 
Rigo, Mestre; Antonio Lotto, Filippo Nador, Scrgio Chierchia, Giuseppe Pizzetti, 
Milano; Giorgio Manioli, Anna Vittoria Mattioli, Modena; Massimo Chiari¢llo, 
Gabriele Conforti, Franco Rengo, Dario Leosco, Salvatore Sederino, Napoli; 
Paolo Rossi, Gianni Sarasso, Novara; Carmelo Cernigliaro, Sergio DaUa Volta, 
Roldano Scognamiglio, Nicoletta Frigato, Padova; Angelo Rained, Luigi 
Messina, Marcello Traina, Palermo; Giuseppe Botti, Antonello Zoni, Walter 
Serra, Mario De Blasi, Parma: Luigi Corea, Ketty Savino, Perugia; Mario 
Mariani, Caterina Palagi, Giovanna Mengozzi, Pisa; Domenico Zanunini, Hero 
Alberto Vi ~ntin, Pordenone; Enrico Adornato, Pasquale Monea, Reggio Cala- 
bria; Armando Dagianti, Lueiano Agati, Filippo Milazzotto, Salvatore Fabio 
Vajola, Enrico Natale, Roma; Paolo Giani, Vittorio Giudici, Seriate; Antonio 
Brusca, Serena Bergerone, Giorgio Golzio, Totino; Francesco Fuflanello, Rob- 
erto Accardi, Trento; Franco Leo, Antonio Galati, GianCarlo Piccinni, Tdcase; 
Giorgio Feruglio, Rosanna Ciani, Udine; Mario Vincenzi, Maurizio Sartori, Hcenza. 
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